PARP Inhibitor Selective Cancer Cell Killing via BRCA Mutation Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using PARP inhibitors often cause damage to non-cancerous cells and are associated with unpleasant side effects, as they need to be administered in combination with radio or chemotherapy treatments to enhance effectiveness.
Innovation Solution
The use of an agent that inhibits the activity of PARP enzymes, specifically targeting cells deficient in homologous recombination, such as those with BRCA1 or BRCA2 mutations, to selectively kill cancer cells without the need for combination therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors are used to treat cancer, then cancer cell killing effectiveness is improved, but damage to non-cancerous cells and side effects increase
Solution Approach 1:
The patent applies local quality by targeting PARP inhibitors specifically at cancer cells with HR defects (such as BRCA1 or BRCA2 mutations) rather than treating all cells uniformly. This selective targeting achieves effective cancer cell killing while minimizing damage to non-cancerous cells, as the treatment is only effective in cells lacking functional homologous recombination repair machinery.
Solution Approach 2:
The patent converts the harmful effect of PARP inhibition into a beneficial selective killing mechanism. By exploiting the fact that cancer cells with HR defects cannot repair DNA damage through homologous recombination, the PARP inhibitor causes lethal DNA damage specifically in these cancer cells while leaving normal cells unharmed, thus transforming a potentially harmful treatment into a selectively beneficial one.
2Ease of operation
If PARP inhibitors are administered alone, then treatment simplicity is improved, but effectiveness is reduced without combination therapy
Solution Approach 1:
The patent applies self-service by demonstrating that PARP inhibitors alone are sufficient to achieve effective cancer cell killing in cells with HR defects. The treatment does not require combination with radiotherapy or chemotherapy to be effective, as the PARP inhibitor itself exploits the cellular deficiency to cause lethal DNA damage, thereby simplifying the treatment regimen while maintaining effectiveness.
3Reliability
If combination therapy with radio or chemotherapy is used, then treatment effectiveness is improved, but device complexity and treatment regimen complexity increase
Solution Approach 1:
The patent applies taking out by extracting the essential effectiveness from combination therapy and achieving it through PARP inhibitor alone. By removing the need for concurrent radiotherapy or chemotherapy while maintaining effective cancer cell killing through PARP inhibition in HR-deficient cells, the treatment regimen is simplified without sacrificing effectiveness.
Data Source
AI summary
The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.